ZA200108174B - Amine derivatives. - Google Patents
Amine derivatives. Download PDFInfo
- Publication number
- ZA200108174B ZA200108174B ZA200108174A ZA200108174A ZA200108174B ZA 200108174 B ZA200108174 B ZA 200108174B ZA 200108174 A ZA200108174 A ZA 200108174A ZA 200108174 A ZA200108174 A ZA 200108174A ZA 200108174 B ZA200108174 B ZA 200108174B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- substituents
- phenyl
- substituent
- dioxothiazolidin
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title claims description 48
- -1 thiocarbamoyl group Chemical group 0.000 claims description 472
- 125000001424 substituent group Chemical group 0.000 claims description 275
- 229910052799 carbon Inorganic materials 0.000 claims description 141
- 125000000217 alkyl group Chemical group 0.000 claims description 126
- 150000001875 compounds Chemical class 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 83
- 125000003545 alkoxy group Chemical group 0.000 claims description 61
- 125000001188 haloalkyl group Chemical group 0.000 claims description 60
- 125000005843 halogen group Chemical group 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- 125000001931 aliphatic group Chemical group 0.000 claims description 28
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 27
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 14
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000004434 sulfur atom Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000002249 Diabetes Complications Diseases 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims description 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 206010012655 Diabetic complications Diseases 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 5
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims description 4
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- 239000000126 substance Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 18
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 11
- 150000002148 esters Chemical class 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 4
- HRVHYQTUUKZNQA-UHFFFAOYSA-N 1-(1-adamantyl)-3-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]urea Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)NC45CC6CC(CC(C6)C4)C5)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O HRVHYQTUUKZNQA-UHFFFAOYSA-N 0.000 claims 2
- MZTARCWHBSKQLJ-UHFFFAOYSA-N 1-[3-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-3-(4-fluorophenyl)urea Chemical compound N=1C2=CC=C(OC=3C=C(NC(=O)NC=4C=CC(F)=CC=4)C=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O MZTARCWHBSKQLJ-UHFFFAOYSA-N 0.000 claims 2
- JWDLDMREELAJRV-UHFFFAOYSA-N 1-[3-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound N=1C2=CC=C(OC=3C=C(NC(=O)NC=4C=CC(=CC=4)C(F)(F)F)C=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O JWDLDMREELAJRV-UHFFFAOYSA-N 0.000 claims 2
- YDEGXCNOYYMTJY-UHFFFAOYSA-N 1-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-3-ethylurea Chemical compound C1=CC(NC(=O)NCC)=CC=C1OC1=CC=C(N=C(COC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)N2C)C2=C1 YDEGXCNOYYMTJY-UHFFFAOYSA-N 0.000 claims 2
- NAAINBRRQYPYHN-UHFFFAOYSA-N 1-benzyl-3-[7-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxynaphthalen-1-yl]urea Chemical compound N=1C2=CC=C(OC=3C=C4C(NC(=O)NCC=5C=CC=CC=5)=CC=CC4=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O NAAINBRRQYPYHN-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- YKCBEIZLLMXLOX-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-2,4-difluorobenzamide Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)C=4C(=CC(F)=CC=4)F)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O YKCBEIZLLMXLOX-UHFFFAOYSA-N 0.000 claims 2
- REPMYONBPYQSHL-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]methanesulfonamide Chemical compound N=1C2=CC=C(OC=3C=CC(NS(C)(=O)=O)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O REPMYONBPYQSHL-UHFFFAOYSA-N 0.000 claims 2
- UEWDVSOOYKEZLG-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]pyridine-3-carboxamide Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)C=4C=NC=CC=4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O UEWDVSOOYKEZLG-UHFFFAOYSA-N 0.000 claims 2
- CWHIFRHINCOTPM-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-3-[2-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]ethyl]urea Chemical compound N=1C2=CC=C(OC=3C=CC(CCNC(=O)NC=4C(=CC(F)=CC=4)F)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O CWHIFRHINCOTPM-UHFFFAOYSA-N 0.000 claims 1
- UAGOWIAHMMDKJU-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxy-2,6-dimethylphenyl]thiourea Chemical compound C=1C(C)=C(NC(=S)NC=2C=CC(Cl)=CC=2)C(C)=CC=1OC(C=C1N2C)=CC=C1N=C2COC(C=C1)=CC=C1CC1SC(=O)NC1=O UAGOWIAHMMDKJU-UHFFFAOYSA-N 0.000 claims 1
- VYCJDFFYLPUNEO-UHFFFAOYSA-N 1-[3-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-3-[2-(trifluoromethyl)phenyl]urea Chemical compound N=1C2=CC=C(OC=3C=C(NC(=O)NC=4C(=CC=CC=4)C(F)(F)F)C=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O VYCJDFFYLPUNEO-UHFFFAOYSA-N 0.000 claims 1
- ISBCTBWYSJLJPG-UHFFFAOYSA-N 1-[3-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-3-phenylurea Chemical compound N=1C2=CC=C(OC=3C=C(NC(=O)NC=4C=CC=CC=4)C=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O ISBCTBWYSJLJPG-UHFFFAOYSA-N 0.000 claims 1
- VGUZMYODIGQFGA-UHFFFAOYSA-N 1-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxy-2,6-dimethylphenyl]-3-(4-nitrophenyl)urea Chemical compound C=1C(C)=C(NC(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)C(C)=CC=1OC(C=C1N2C)=CC=C1N=C2COC(C=C1)=CC=C1CC1SC(=O)NC1=O VGUZMYODIGQFGA-UHFFFAOYSA-N 0.000 claims 1
- SRLJUIPXCNUBDG-UHFFFAOYSA-N 1-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-3-phenylurea Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)NC=4C=CC=CC=4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O SRLJUIPXCNUBDG-UHFFFAOYSA-N 0.000 claims 1
- GQUAFKLVDHDXBQ-UHFFFAOYSA-N 1-[7-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxynaphthalen-1-yl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C1=C2)=CC=CC1=CC=C2OC1=CC=C(N=C(COC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)N2C)C2=C1 GQUAFKLVDHDXBQ-UHFFFAOYSA-N 0.000 claims 1
- IXTLJGIFZCZPHO-UHFFFAOYSA-N 1-benzyl-3-[7-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxynaphthalen-1-yl]thiourea Chemical compound N=1C2=CC=C(OC=3C=C4C(NC(=S)NCC=5C=CC=CC=5)=CC=CC4=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IXTLJGIFZCZPHO-UHFFFAOYSA-N 0.000 claims 1
- DEHUXKDDQUKRAW-UHFFFAOYSA-N 3-chloro-n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]benzamide Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)C=4C=C(Cl)C=CC=4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O DEHUXKDDQUKRAW-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- KFSJPZZPCJEMBY-UHFFFAOYSA-N n-[2-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]ethyl]pyridine-3-carboxamide Chemical compound N=1C2=CC=C(OC=3C=CC(CCNC(=O)C=4C=NC=CC=4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O KFSJPZZPCJEMBY-UHFFFAOYSA-N 0.000 claims 1
- ZANZLUPRQFRTPW-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]-n-hexylacetamide Chemical compound C1=CC(N(C(C)=O)CCCCCC)=CC=C1OC1=CC=C(N=C(COC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)N2C)C2=C1 ZANZLUPRQFRTPW-UHFFFAOYSA-N 0.000 claims 1
- ZKHLYSRUNNGEBM-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]benzamide Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)C=4C=CC=CC=4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O ZKHLYSRUNNGEBM-UHFFFAOYSA-N 0.000 claims 1
- CVRCPCWIPMRMCY-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]cyclopentanecarboxamide Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)C4CCCC4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O CVRCPCWIPMRMCY-UHFFFAOYSA-N 0.000 claims 1
- LUZIKZKELDJVJM-UHFFFAOYSA-N n-[4-[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-3-methylbenzimidazol-5-yl]oxyphenyl]pyridine-4-carboxamide Chemical compound N=1C2=CC=C(OC=3C=CC(NC(=O)C=4C=CN=CC=4)=CC=3)C=C2N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O LUZIKZKELDJVJM-UHFFFAOYSA-N 0.000 claims 1
- JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 208000002177 Cataract Diseases 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- 102000016912 Aldehyde Reductase Human genes 0.000 description 3
- 108010053754 Aldehyde reductase Proteins 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical group CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 description 2
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 description 2
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 description 2
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003262 anti-osteoporosis Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002213 calciumantagonistic effect Effects 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000027950 fever generation Effects 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000002995 2-(trifluoromethyl)benzoyl group Chemical group FC(C1=C(C(=O)*)C=CC=C1)(F)F 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000003858 2-ethylbutoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])O*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004924 2-naphthylethyl group Chemical group C1=C(C=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000003890 2-phenylbutyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000002981 3-(trifluoromethyl)benzoyl group Chemical group FC(C=1C=C(C(=O)*)C=CC1)(F)F 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002999 4-(trifluoromethyl)benzoyl group Chemical group FC(C1=CC=C(C(=O)*)C=C1)(F)F 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 125000002946 cyanobenzyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006640 cycloheptyl carbonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 125000006333 difluoro benzoyl group Chemical group 0.000 description 1
- 125000006287 difluorobenzyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 125000006182 dimethyl benzyl group Chemical group 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical group C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 125000006332 fluoro benzoyl group Chemical group 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 150000001475 oxazolidinediones Chemical class 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical class O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000006510 trifluorobenzyl group Chemical group 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrrole Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9998199 | 1999-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200108174B true ZA200108174B (en) | 2003-01-06 |
Family
ID=14261854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200108174A ZA200108174B (en) | 1999-04-07 | 2001-10-04 | Amine derivatives. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6562849B1 (zh) |
| EP (1) | EP1167366B1 (zh) |
| KR (1) | KR100588284B1 (zh) |
| CN (1) | CN1162427C (zh) |
| AT (1) | ATE466861T1 (zh) |
| AU (1) | AU757729B2 (zh) |
| BR (1) | BR0009594A (zh) |
| CA (1) | CA2369971A1 (zh) |
| CZ (1) | CZ300691B6 (zh) |
| DE (1) | DE60044342D1 (zh) |
| ES (1) | ES2343104T3 (zh) |
| HK (1) | HK1039940B (zh) |
| HU (1) | HUP0200996A3 (zh) |
| ID (1) | ID30498A (zh) |
| IL (2) | IL145759A0 (zh) |
| MX (1) | MXPA01010108A (zh) |
| NO (1) | NO321158B1 (zh) |
| NZ (1) | NZ514662A (zh) |
| PL (1) | PL351878A1 (zh) |
| RU (1) | RU2221796C2 (zh) |
| TR (1) | TR200103183T2 (zh) |
| TW (1) | TW550264B (zh) |
| WO (1) | WO2000061581A1 (zh) |
| ZA (1) | ZA200108174B (zh) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003033494A1 (fr) * | 2001-10-17 | 2003-04-24 | Sankyo Company, Limited | Derive de benzimidazole |
| WO2003032988A1 (fr) * | 2001-10-17 | 2003-04-24 | Sankyo Company, Limited | Composition pharmaceutique |
| WO2003082865A1 (fr) * | 2002-04-01 | 2003-10-09 | Sankyo Company, Limited | Composition médicinale antitumorale |
| BR0309940A (pt) | 2002-05-08 | 2005-02-09 | Bayer Healthcare Ag | Derivados de hidróxi-tetraidro-naftaleniluréia |
| AU2003246187A1 (en) * | 2002-06-25 | 2004-01-06 | Sankyo Company, Limited | MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR |
| TW200408628A (en) * | 2002-08-02 | 2004-06-01 | Sankyo Co | Resorcinol and its derivatives |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| JP2007532484A (ja) | 2004-03-16 | 2007-11-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法 |
| CA2584342C (en) * | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| WO2007047397A2 (en) * | 2005-10-13 | 2007-04-26 | Smithkline Beecham Corporation | Phenol ethers as modulators of the opioid receptors |
| US20070185055A1 (en) * | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
| TW201336497A (zh) | 2007-02-08 | 2013-09-16 | Daiichi Sankyo Co Ltd | 噻唑啶二酮化合物之結晶型及其製法 |
| US20110160462A1 (en) * | 2008-07-31 | 2011-06-30 | Daiichi Sankyo Company, Limited | Crystalline forms of thiazolidinedione compound and its manufacturing method |
| JPWO2010013768A1 (ja) * | 2008-07-31 | 2012-01-12 | 第一三共株式会社 | チアゾリジンジオン化合物の結晶及びその製造方法 |
| KR20120101017A (ko) | 2009-11-26 | 2012-09-12 | 다이이찌 산쿄 가부시키가이샤 | 6-치환 1-메틸-1ｈ-벤즈이미다졸 유도체의 제조법 및 그 제조 중간체 |
| US9376727B2 (en) | 2010-05-25 | 2016-06-28 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically truncated probes |
| WO2015160772A1 (en) * | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
| KR101480674B1 (ko) * | 2014-07-03 | 2015-01-09 | 주식회사 큐리언트 | 화합물 및 염증성 질환 치료용 약학적 조성물 |
| KR101496094B1 (ko) * | 2014-07-04 | 2015-02-25 | 주식회사 큐리언트 | 화합물 및 염증성 질환 치료용 약학적 조성물 |
| KR101496096B1 (ko) * | 2014-07-17 | 2015-03-02 | 주식회사 큐리언트 | 화합물 및 염증성 질환 치료용 약학적 조성물 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| EP3668840A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR940000623B1 (ko) | 1989-05-15 | 1994-01-26 | 히페리온 카탈리시스 인터내셔날 | 마이크로 탄소섬유 산화처리방법 |
| FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CZ282548B6 (cs) | 1992-01-22 | 1997-08-13 | F. Hoffmann-La Roche Ag | Farmaceutický přípravek |
| WO1994015901A1 (en) | 1993-01-11 | 1994-07-21 | Ligand Pharmaceuticals Inc. | Compounds having selectivity for retinoid x receptors |
| TW268952B (zh) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| WO1994022846A1 (en) * | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
| JP3300869B2 (ja) | 1993-08-09 | 2002-07-08 | 武田薬品工業株式会社 | ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
| IL113313A (en) * | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
| US5703096A (en) * | 1994-10-07 | 1997-12-30 | Sankyo Company, Limited | Oxime derivatives, their preparation and their therapeutic use |
| TW403748B (en) * | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
| DE69516903T2 (de) | 1994-12-30 | 2000-10-26 | Ligand Pharmaceuticals, Inc. | Retinoid trienverbindungen und verfahren |
| CZ293016B6 (cs) | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
| JPH09165371A (ja) * | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
| BR9711098B1 (pt) | 1996-07-01 | 2011-10-04 | compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas. | |
| JP3268242B2 (ja) | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
| AU5727998A (en) | 1996-12-31 | 1998-07-31 | Salk Institute For Biological Studies, The | Treatment of liposarcomas using a combination of thiazolidinediones and retinoidx receptor selective agonists |
| NZ503794A (en) * | 1997-10-08 | 2002-09-27 | Sankyo Co | Benzimidazole and imidazopyridine derived heterocyclic compounds, pharmaceutical compositions and uses thereof |
-
2000
- 2000-04-06 NZ NZ514662A patent/NZ514662A/xx unknown
- 2000-04-06 DE DE60044342T patent/DE60044342D1/de not_active Expired - Lifetime
- 2000-04-06 AU AU36708/00A patent/AU757729B2/en not_active Ceased
- 2000-04-06 CZ CZ20013592A patent/CZ300691B6/cs not_active IP Right Cessation
- 2000-04-06 TW TW089106330A patent/TW550264B/zh active
- 2000-04-06 ES ES00915362T patent/ES2343104T3/es not_active Expired - Lifetime
- 2000-04-06 PL PL00351878A patent/PL351878A1/xx not_active Application Discontinuation
- 2000-04-06 WO PCT/JP2000/002216 patent/WO2000061581A1/ja not_active Application Discontinuation
- 2000-04-06 ID IDW00200102147A patent/ID30498A/id unknown
- 2000-04-06 CN CNB008086362A patent/CN1162427C/zh not_active Expired - Fee Related
- 2000-04-06 MX MXPA01010108A patent/MXPA01010108A/es active IP Right Grant
- 2000-04-06 BR BR0009594-0A patent/BR0009594A/pt not_active IP Right Cessation
- 2000-04-06 IL IL14575900A patent/IL145759A0/xx unknown
- 2000-04-06 EP EP00915362A patent/EP1167366B1/en not_active Expired - Lifetime
- 2000-04-06 RU RU2001127082/04A patent/RU2221796C2/ru active
- 2000-04-06 HU HU0200996A patent/HUP0200996A3/hu unknown
- 2000-04-06 AT AT00915362T patent/ATE466861T1/de not_active IP Right Cessation
- 2000-04-06 CA CA002369971A patent/CA2369971A1/en not_active Abandoned
- 2000-04-06 TR TR2001/03183T patent/TR200103183T2/xx unknown
- 2000-04-06 KR KR1020017012728A patent/KR100588284B1/ko not_active IP Right Cessation
-
2001
- 2001-10-04 ZA ZA200108174A patent/ZA200108174B/en unknown
- 2001-10-04 IL IL145759A patent/IL145759A/en not_active IP Right Cessation
- 2001-10-05 US US09/971,634 patent/US6562849B1/en not_active Expired - Fee Related
- 2001-10-05 NO NO20014847A patent/NO321158B1/no not_active IP Right Cessation
-
2002
- 2002-02-26 HK HK02101455.4A patent/HK1039940B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200108174B (en) | Amine derivatives. | |
| ES2398313T3 (es) | 5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes | |
| DE69801680T2 (de) | Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten | |
| RU2188013C2 (ru) | Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность | |
| RU2190425C2 (ru) | Способ и композиция для лечения и предупреждения гиперурикемии | |
| KR950703539A (ko) | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) | |
| US6452014B1 (en) | Telomerase inhibitors and methods of their use | |
| EA005680B1 (ru) | Ингибиторы гиразы и их применение для лечения бактериальной инфекции | |
| JP5021307B2 (ja) | 糖尿病治療のためのベンゾチアゾール誘導体 | |
| KR20080012304A (ko) | 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약 | |
| CN101535303A (zh) | 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物 | |
| ZA200007076B (en) | A pharmaceutical combination comprising a COX-2 inhibitor and iNOS inhibitor. | |
| RU2009122505A (ru) | Способы сохранения функции почек с использованием ингибиторов ксантин оксидоредуктазы | |
| RU2001127082A (ru) | Производные аминов | |
| WO1999059586A1 (en) | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis | |
| KR960007526B1 (ko) | 2-피리미디닐-1-피페라진 유도체를 함유하는 약제학적 조성물 | |
| EP1040829A2 (en) | Prokinetic agents for treating gastric hypomotility and related disorders | |
| EP2188272B1 (en) | Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases | |
| MX2007013741A (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica. | |
| EP1353669B1 (en) | Method for treating glaucoma | |
| ZA200508481B (en) | Heteroaromatic pentacyclic compound and medicinal use thereof | |
| JP4197387B2 (ja) | アミン誘導体化合物 | |
| JP2002179568A (ja) | アミン誘導体化合物を含有する糖尿病予防剤、治療剤 | |
| US20140024687A1 (en) | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists | |
| KR20010029716A (ko) | 편두통 치료용 복합 처방법 |